GB2137493A - Weight reducing composition - Google Patents

Weight reducing composition Download PDF

Info

Publication number
GB2137493A
GB2137493A GB08308414A GB8308414A GB2137493A GB 2137493 A GB2137493 A GB 2137493A GB 08308414 A GB08308414 A GB 08308414A GB 8308414 A GB8308414 A GB 8308414A GB 2137493 A GB2137493 A GB 2137493A
Authority
GB
United Kingdom
Prior art keywords
tablet
potassium chloride
diuretic
appetite
frusemide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08308414A
Other versions
GB8308414D0 (en
Inventor
Dr Kishan Narain Mathur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB08308414A priority Critical patent/GB2137493A/en
Publication of GB8308414D0 publication Critical patent/GB8308414D0/en
Publication of GB2137493A publication Critical patent/GB2137493A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition consisting of a appetite suppressants a first appetite suppressant and a second diuretic and potassium chloride in slow release. The composition being such that on oral administration appetite suppressants is absorbed first and the second diuretic. A particularly preferred embodiment comprises an outer layer of Diethylpropion Hydrochloride an intermediate layer of Frusemide and an inner layer of potassium chloride Diethylpropion Hydrochloride act first and then Frusemide while potassium chloride gives slow absorbtion throughout.

Description

SPECIFICATION Obee multi pack Background of the invention This invention relates to a pharmaceutical composition for administration to humans suffering from over weight with water retention.
Known compositions for administration to humans suffering from moderate to severe obesity include the following Diethylpropion Hydrochlor + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride + Nicotiamide. However, the advantages discussed below of compositions and tablets in accordance with the present invention are not exhibited by these prior compositions and it is an object of the present invention to provide an improved composition with advantage of diuretic along with appetite suppressants.
Summary of the invention According to one aspect of this invention there is provided a pharmaceutical composition comprising Anorexia first and a diuretic effect second and slow release of potassium chloride on oral administration.
Preferably, a hunger control of appetite is used suitable compounds being Diethylpropion Hydrochloride as though it is to be appreciated that many other anoretic (appetite supppressant) drugs could be used. Most anoretics have high side effects and contraindications and have interaction with other drugs, so Diethylpropion Hydrochloride is choosen.
According to a second aspect of the invention, there is provided a tablet comprising of a composition which provides diuretic and potassium chloride.
Description ofpreferred embodiments So that the present invention may be more readily understood and so that further features thereof may be appreciated, preferred embodiments of the invention will now be discussed by way of example.
A preferred embodiment of a tablet in accordance with the invention comprises a central core of Frusemide 20mg with surrounded by Potassium Chloride 600mg in slow release layer and outer layer of 70mg Diethylpropion Hydrochloride.
The tablet is intended for one in the morning after breakfast by oral administration not longer than 6 - 8 weeks at a time.
Tablet in accordance with the invention have been found to be useful in reducing or eliminating hunger and control the appetite by outer layer of Diethylpropion Hydrochloride.
Preferrably the diuretic Frusemide inhibit resorbtion from the ascending loop of henle in the renal tubule and provide powerful dieretic in patients with oedema with obesity. Potassium chloride replaces any loss due to diuretictherepy.
In general, man tends to eat according to the time of the day rather that to the activity of feeding centres, although activity of the satiety centre is probably important in determining the amount of food ingested. It has been found that the first effect of the tablet is a reduction of the patients appetite.
In many patients of idiopathic oedema with obesity Frusemide and Potassium Chloride play a great role in reducing extra cellular fluid from the body.
The specific tablets described above contains a sustained-release Diethylpropion Hydrochloride in outer layer. Frusemide in Intermediate layer and third layer of potassium chloride.
Although the formation of such a tablet may be more time consuming than the preparation of the specific example described above. Such a modified tablet will be more useful in obesity with excessive fluid retention subjects.
Administration of tablet in accordance with the invention would be contra-inidicated in the following conditions: Glaucoma. Hyper-excitable state (thyrotoxicosis) concurrent administation of Maio's.
Hyperkalaemia, Liver diseases, Addison disease.
Great caution should be used in cardiovascular disease, peptic ulceration, epilepsy, diabetes, depression, unstable personality, pregnancy.
Common side effects are agitation, insomnia, tachycardia, gastro-intestinal disturbances, dizziness, tremor, restlessness, dry-mouth, headaches, tolerance and dependence may occur.
The reader skilled in the art will appreciate that many variations and modofications are possible but this is the first formula with Diuretic and Potassium Chloride with an appetite suppressant.
1. A pharmaceutical composition comprising of a hunger "The control of appetite", Anoretic and a diuretic along with Potassium Chloride. The composition being such that on oral administration.
Diethylpropion Hydrochloride attach on feeding centres in the lateral Hypothalmus.
2. A composition according to claim 1 where in a non-amphetamine is used.
3. A composition according to claim 2 where in the Diuretic is Frusemide.
4. A composition according to claim 2 Potassium Chloride is used to maintain body salts.
5. A tablet or pill comprising a composition according to any one of the preceding claims.
6. A method of treating a person or animals suffering from obesity with excessive body fluids retension or overweight with Idiopathis oedema.
7. A method of treating a person by orally administering one single tablet or pill in the morning.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (7)

**WARNING** start of CLMS field may overlap end of DESC **. SPECIFICATION Obee multi pack Background of the invention This invention relates to a pharmaceutical composition for administration to humans suffering from over weight with water retention. Known compositions for administration to humans suffering from moderate to severe obesity include the following Diethylpropion Hydrochlor + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride + Nicotiamide. However, the advantages discussed below of compositions and tablets in accordance with the present invention are not exhibited by these prior compositions and it is an object of the present invention to provide an improved composition with advantage of diuretic along with appetite suppressants. Summary of the invention According to one aspect of this invention there is provided a pharmaceutical composition comprising Anorexia first and a diuretic effect second and slow release of potassium chloride on oral administration. Preferably, a hunger control of appetite is used suitable compounds being Diethylpropion Hydrochloride as though it is to be appreciated that many other anoretic (appetite supppressant) drugs could be used. Most anoretics have high side effects and contraindications and have interaction with other drugs, so Diethylpropion Hydrochloride is choosen. According to a second aspect of the invention, there is provided a tablet comprising of a composition which provides diuretic and potassium chloride. Description ofpreferred embodiments So that the present invention may be more readily understood and so that further features thereof may be appreciated, preferred embodiments of the invention will now be discussed by way of example. A preferred embodiment of a tablet in accordance with the invention comprises a central core of Frusemide 20mg with surrounded by Potassium Chloride 600mg in slow release layer and outer layer of 70mg Diethylpropion Hydrochloride. The tablet is intended for one in the morning after breakfast by oral administration not longer than 6 - 8 weeks at a time. Tablet in accordance with the invention have been found to be useful in reducing or eliminating hunger and control the appetite by outer layer of Diethylpropion Hydrochloride. Preferrably the diuretic Frusemide inhibit resorbtion from the ascending loop of henle in the renal tubule and provide powerful dieretic in patients with oedema with obesity. Potassium chloride replaces any loss due to diuretictherepy. In general, man tends to eat according to the time of the day rather that to the activity of feeding centres, although activity of the satiety centre is probably important in determining the amount of food ingested. It has been found that the first effect of the tablet is a reduction of the patients appetite. In many patients of idiopathic oedema with obesity Frusemide and Potassium Chloride play a great role in reducing extra cellular fluid from the body. The specific tablets described above contains a sustained-release Diethylpropion Hydrochloride in outer layer. Frusemide in Intermediate layer and third layer of potassium chloride. Although the formation of such a tablet may be more time consuming than the preparation of the specific example described above. Such a modified tablet will be more useful in obesity with excessive fluid retention subjects. Administration of tablet in accordance with the invention would be contra-inidicated in the following conditions: Glaucoma. Hyper-excitable state (thyrotoxicosis) concurrent administation of Maio's. Hyperkalaemia, Liver diseases, Addison disease. Great caution should be used in cardiovascular disease, peptic ulceration, epilepsy, diabetes, depression, unstable personality, pregnancy. Common side effects are agitation, insomnia, tachycardia, gastro-intestinal disturbances, dizziness, tremor, restlessness, dry-mouth, headaches, tolerance and dependence may occur. The reader skilled in the art will appreciate that many variations and modofications are possible but this is the first formula with Diuretic and Potassium Chloride with an appetite suppressant. CLAIMS
1. A pharmaceutical composition comprising of a hunger "The control of appetite", Anoretic and a diuretic along with Potassium Chloride. The composition being such that on oral administration.
Diethylpropion Hydrochloride attach on feeding centres in the lateral Hypothalmus.
2. A composition according to claim 1 where in a non-amphetamine is used.
3. A composition according to claim 2 where in the Diuretic is Frusemide.
4. A composition according to claim 2 Potassium Chloride is used to maintain body salts.
5. A tablet or pill comprising a composition according to any one of the preceding claims.
6. A method of treating a person or animals suffering from obesity with excessive body fluids retension or overweight with Idiopathis oedema.
7. A method of treating a person by orally administering one single tablet or pill in the morning.
GB08308414A 1983-03-28 1983-03-28 Weight reducing composition Withdrawn GB2137493A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08308414A GB2137493A (en) 1983-03-28 1983-03-28 Weight reducing composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08308414A GB2137493A (en) 1983-03-28 1983-03-28 Weight reducing composition

Publications (2)

Publication Number Publication Date
GB8308414D0 GB8308414D0 (en) 1983-05-05
GB2137493A true GB2137493A (en) 1984-10-10

Family

ID=10540316

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08308414A Withdrawn GB2137493A (en) 1983-03-28 1983-03-28 Weight reducing composition

Country Status (1)

Country Link
GB (1) GB2137493A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005769A1 (en) * 1991-09-17 1993-04-01 Martti Lauri Antero Marvola Controlled release pharmaceutical preparations
US7268161B2 (en) 1999-10-04 2007-09-11 Hinz Martin C Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US7547723B2 (en) 1999-10-04 2009-06-16 Hinz Martin C Comprehensive pharmacologic therapy for treatment of a dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1103238A (en) * 1966-11-22 1968-02-14 Sandoz Products Ltd Improvements in or relating to pharmaceutical tablets
GB1117093A (en) * 1964-08-24 1968-06-12 Nova Medicinal compositions with synergistic diuretic and anorexic activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1117093A (en) * 1964-08-24 1968-06-12 Nova Medicinal compositions with synergistic diuretic and anorexic activity
GB1103238A (en) * 1966-11-22 1968-02-14 Sandoz Products Ltd Improvements in or relating to pharmaceutical tablets

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005769A1 (en) * 1991-09-17 1993-04-01 Martti Lauri Antero Marvola Controlled release pharmaceutical preparations
US5849330A (en) * 1991-09-17 1998-12-15 Orion-Yhtyma Oy Controlled release pharmaceutical
US7268161B2 (en) 1999-10-04 2007-09-11 Hinz Martin C Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US7547723B2 (en) 1999-10-04 2009-06-16 Hinz Martin C Comprehensive pharmacologic therapy for treatment of a dysfunction

Also Published As

Publication number Publication date
GB8308414D0 (en) 1983-05-05

Similar Documents

Publication Publication Date Title
CA1176981A (en) Method for preventing body fat deposition in mammals
EP0007691B1 (en) Compositions for use in decreasing appetite for calories as carbohydrates
PH20568A (en) Dietary and pharmaceutical uses of methyl sulfonylmethane and compositions comprising it
US4315028A (en) Method of treatment of rheumatoid arthritis
PL188052B1 (en) Combined preparation containing (4-trifluoromethyl) 5-methylisoxazole-4-carboxylic anilide and n-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycortonamide
KR960000217A (en) L-carnitine salts and compositions containing them
NL193440C (en) Pharmaceutical preparation with analgesic effect.
US4282215A (en) Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
GB2137493A (en) Weight reducing composition
US4025624A (en) Phenylalkylamines and phenylalkylureas in combinations to suppress gastric bleeding in aspirin therapy
EP0109281A1 (en) Compositions comprising flurbiprofen or ibuprofen
US4428951A (en) Long acting pharmaceutical composition
US4855293A (en) Anti-inflammatory compositions comprising a systemic non-steroidal anti-inflammatory drug and a cyclopentyl ether
KR20070086007A (en) Medicinal composition for treating diabetes
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
NL193821C (en) Pharmaceutical preparation.
US4493827A (en) Method of inducing sleep
JPH0136804B2 (en)
EP0178122B1 (en) Improved piroxicam-containing antiinflammatory compositions
EP0024690B1 (en) Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
Boelaert et al. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment
US3639597A (en) Pharmaceutical compositions containing cholanic acid conjugates
Roth The new look in drugs: Is' longer lasting'better?
JPS5862114A (en) Pharmaceutical composition for preventing thrombocyte agglutination
US4499106A (en) Lipolytic composition and method of treating obesity

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)